Dr. Sonal Paul
Claim this profileSinai Hospital of Baltimore
Studies Rectal Cancer
Studies Colon Cancer
4 reported clinical trials
9 drugs studied
Area of expertise
1Rectal Cancer
Stage III
Stage II
MSH2 negative
2Colon Cancer
Stage III
MSS positive
MMR positive
Affiliated Hospitals
Clinical Trials Sonal Paul is currently running
Chemotherapy + Immunotherapy
for Esophageal and Gastric Cancer
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Chemotherapy Tailored by ctDNA Status
for Colon Cancer
This trial tests if a blood test for cancer DNA can help decide if colon cancer patients need more treatment after surgery. The test looks for cancer DNA in the blood to predict if the cancer might come back and to guide further treatment.
Recruiting1 award Phase 2 & 3
More about Sonal Paul
Clinical Trial Related2 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Sonal Paul has experience with
- MFOLFIRINOX
- Irinotecan
- Oxaliplatin
- CAPOX
- MFOLFOX6
- Signatera Test
Breakdown of trials Sonal Paul has run
Esophageal Adenocarcinoma
Esophageal cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sonal Paul specialize in?
Sonal Paul focuses on Rectal Cancer and Colon Cancer. In particular, much of their work with Rectal Cancer has involved Stage III patients, or patients who are Stage II.
Is Sonal Paul currently recruiting for clinical trials?
Yes, Sonal Paul is currently recruiting for 2 clinical trials in Baltimore Maryland. If you're interested in participating, you should apply.
Are there any treatments that Sonal Paul has studied deeply?
Yes, Sonal Paul has studied treatments such as mFOLFIRINOX, Irinotecan, Oxaliplatin.
What is the best way to schedule an appointment with Sonal Paul?
Apply for one of the trials that Sonal Paul is conducting.
What is the office address of Sonal Paul?
The office of Sonal Paul is located at: Sinai Hospital of Baltimore, Baltimore, Maryland 21215 United States. This is the address for their practice at the Sinai Hospital of Baltimore.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.